Philips is launching a new clinical trial aimed at reducing the amount of radiation used during coronary procedures, with an ...

Schrödinger is laying off 60 staffers, or about 7% of its workforce, in an effort to save cash and boost efficiency. | ...

Johnson & Johnson has put forward a clinical study exploring the use of its Shockwave Medical division’s vessel-clearing ...

Roughly five months after AstraZeneca scrapped a major investment plan in its home country, the United Kingdom has found a ...

A dementia-focused transatlantic venture capital initiative has secured $269 million in commitments for its second fund. | A ...

Blueprint Medicines is revising a pact with VantAI again, this time adding a focus for historically “undruggable” targets and ...

Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China ...

Pacibekitug, an antibody targeting interleukin-6, hit the primary endpoint in the phase 2 Tranquility trial by sharply ...

RegenXBio will fill its coffers with up to $250 million by monetizing more royalty rights for Novartis-partnered Zolgensma, ...

CRISPR Therapeutics is paying $25 million upfront to work on multiple siRNA targets with Sirius Tx with an early focus on the ...

Fierce 15 nominations are open! We're searching for the most innovative, resourceful and visionary biotechs leading the way ...

Boehringer Ingelheim’s long-awaited phase 3 lung disease data received a muted reception from analysts who labeled ...